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 Introduction
Modiﬁed life-attenuated vaccines (MLVs) comprise
eakened versions of pathogens that often confer long-
sting immunity similar to that seen in natural infection.
netheless, adverse events, including the potential to
use disease, may occur (Pulendran and Ahmed, 2011).
creased efforts in current vaccine design lie in
e enhancement of the immune responses of weak
experimental and commercial killed and subunit vac-
cines by means of using adjuvants, ingredients that directly
or indirectly contribute to vaccine efﬁcacy (Levitz and
Golenbock, 2012). Although key components of vaccine
formulations, the mechanisms by which adjuvants enhance
immunity are not fully understood (Martin-Fontecha et al.,
2004). Speciﬁcally, whether adjuvants impact cellular
immunity triggered by immunogenic MLVs have not been
explored in deep.
The porcine reproductive and respiratory syndrome
(PRRS) is caused by an enveloped RNA virus-(PRRSV),
affecting pigs worldwide and leading to great economic
losses in swine industry (Holtkamp et al., 2013). Infections
can occur in pigs of all ages, provoking respiratory
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Adjuvants enhance both the magnitude and duration of immune responses, therefore
representing a central component of vaccines. The nature of the adjuvant can determine
the particular type of immune response, which may be skewed toward cytotoxic T cell
(CTL) responses, antibody responses, or particular classes of T helper (Th) responses and
antibody isotypes. Traditionally, adjuvants have been added to intrinsically poor
immunogenic vaccines, such as those using whole killed organisms or subunit vaccines.
Here, we have compared cellular immune responses induced by the immunogenic
modiﬁed life-attenuated vaccine Ingelvac PRRS1 MLV when administered alone or in
combination with carbopol, a widely used adjuvant in veterinary medicine. Using
functional readouts (IFN-g ELISpot and cell proliferation) and analyzing phenotypical
hallmarks of CD4T cell differentiation, we show that carbopol improves cellular immunity
by inducing early IFN-g-producing cells and by preferentially driving T cell differentiation
to effector phenotypes. Our data suggest that adjuvants may enhance and modulate life-
attenuated – not only subunit/inactivated – vaccines.
 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
 Corresponding author. Tel.: +49 6132 77 142033.
E-mail address: rimma.libanova@boehringer-ingelheim.com
 Libanova).
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K.H. Mair et al. / Veterinary Microbiology 176 (2015) 352–357 353yndromes, cyanosis of extremities as well as reproductive
ilures in sows (Christianson et al., 1992). Two main PRRSV
enotypes, the European (type 1) and the North-american
ype 2) (Han et al., 2013) have been described so far.
In this study we investigated the potential of a selected
arbomer adjuvant (Carbopol1 971P) to impact the
ellular immune response induced by vaccination of pigs
ith a modiﬁed live-attenuated vaccine. The immune
esponse after a single immunization with Ingelvac PRRS1
LV (Boehringer Ingelheim) delivered with or without
arbopol was evaluated at different time points. Our
esults provide evidence to consider carbopol as optimal
djuvant to improve the early cellular immunity elicited by
LVs.
. Material and methods
.1. Animals
In total, 24 piglets (crossbreed Landrace, Large White and
ietrain) were obtained at the age of six weeks from a
onventional piglet producing farm in Austria. The farm is
nown to be free of PRRSV, which is tested at distinct
tervals by the University Clinic for Swine, University of
eterinary Medicine, Vienna. The animals chosen for the
tudy were all clinically healthy and were negative for
RRSV-speciﬁc antibodies (tested by ELISA at study day (SD)-
; PRRS X3, IDEXX, Ludwigsburg, Germany). Experimental
rocedures were approved by the institutional ethics
ommittee, the Advisory Committee for Animal Experiments
12 of Law for Animal Experiments, Tierversuchsgesetz–
VG) and the Federal Ministry for Science and Research
eference number BMWF-68.205/0083-II/3b/2013).
.2. Immunizations (Table 1)
Animals were immunized once intramuscularly in the
eck at SD0 with modiﬁed live-attenuated PRRS virus
ngelvac PRRS1 MLV, Boehringer Ingelheim) in the
resence or the absence of a 0.1% solution of carbopol
arbopol1 971P NF Polymer, Lubrizol, Cleveland, OH) in
BS. PBS and carbopol served as negative control groups.
ll animals received a total volume of 2 mL.
.3. PBMC
At SD14 and 21, peripheral blood mononuclear
ells (PBMC) were isolated from heparinized blood
samples by density gradient centrifugation as described
elsewhere.
2.4. IFN-g ELISpot
96 well plates with a polyvinylidene ﬂuoride mem-
brane (Millipore, Billerica, USA) were coated over night
with 100 mL/well of a monoclonal antibody speciﬁc to
porcine IFN-g (clone pIFN-g, Mabtech, Nacka Strand,
Sweden) at 4 8C, adjusted to 10 mg/mL. After washing,
freshly isolated PBMC were added to wells (3  105 PBMC
and 200 mL ﬁnal volume per well) in cell culture medium.
This consisted of RPMI 1640 with stable glutamine (PAN
Biotech, Aidbach, Germany) supplemented with 10% (v/v)
heat inactivated foetal calf serum (FCS, PAA, Pasching,
Austria), 100 IU/mL penicillin and 0.1 mg/mL streptomycin
(PAA). Cells were stimulated with different concentrations
of virus (ATCC VR2332; MOI = 1.0, 0.5, 0.25; grown on the
MA-104 cell line). As control group, cell culture superna-
tant of non-infected MA-104 cells (mock control to virus)
was added in an equal amount as for virus MOI = 1.0 to
PBMC. Additionally, cells without stimulus (medium only)
were tested as negative control in parallel. Concanavalin A
(ConA, 3 mg/mL, GE Healthcare, Pittsburgh, USA) stimulat-
ed cultures where used as a positive control. All samples
were analyzed in duplicates. After incubation at 37 8C and
5% CO2 for 24 h, PBMC were discarded and plates incubated
with 100 mL/well of a second IFN-g-speciﬁc biotinylated
antibody (clone PAN, Mabtech, 1 mg/mL) for one hour, and
for one additional hour with streptavidin alkaline phospha-
tase (Roche, Mannheim, Germany; 1:2000; 100 mL/well).
Finally, 5-bromo-4-chloro-3-indolyl phosphate/nitro blue
tetrazolium substrate (100 mL/well, Sigma-Aldrich, Vienna,
Austria) was added for ﬁve minutes. Spot development was
stopped by washing plates under tap water and enumerated
in a camera-based automated counting system (AID,
Straßberg, Germany). Animals with more than 30 spots
were arbitrarily considered responders. This number is at
least 2.5 times above the average number of spots of all
animals in control groups (PBS and carbopol) of both SD14
and SD21 when stimulated with PRRSV (mock-stimulated
cells were always below this cut off).
2.5. Cell proliferation assay
PBMC were adjusted to 5–20  106 cells per mL PBS.
1 mL of a 5 mM solution of the Violet Cell Trace dye (Life
Technologies, Carlsbad CA, US) was added per mL initial
cell solution. After incubation for 10 min at 37 8C, 2 mL FCS
(PAA) were added per mL initial cell solution, followed by
an incubation at room temperature in the dark for 15 min
and washed thoroughly afterwards. For in vitro stimulation
cells were added to 96-well round-bottom plates at a
concentration of 2  105 PBMC per well in a ﬁnal
incubation volume of 200 mL and stimulated with life
virus (ATCC VR 2332, US strain, MOI = 1.0). In parallel
equivalent mock control was carried out as negative
control. Additionally, cells cultured in medium only served
as additional negative control. After incubation at 37 8C
and 5% CO2 for four days, PBMC were further used in multi-
colour ﬂow cytometry.
able 1
tudy design and animal groups. The four groups of animals used for the
udy are listed, including details to the immunization procedure. PBS,
hosphate buffered saline; MLV, modiﬁed live-vaccine Ingelvac1 PRRS
oehringer Ingelheim); TCID50, tissue culture infectious dose, at least
04.9 live virus per dose, according to Boehringer Ingelheim data sheet.
Treatment Animals/
Group
Animal
code
Dose MLV
(TCID50)
PBS 6 #1–6 n/a
Carbopol 0.1% 6 #7–12 n/a
MLV 6 #13–18 104.9 live virus
MLV + carbopol 0.1% 6 #19–24 104.9 live virus
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The following primary antibodies were used for cell
rface staining: PerCP-Cy5.5-conjugated anti-CD3 (IgG2a,
ne BB23 8E6 8C8, BD Biosciences, San Jose, CA, USA),
C-conjugated anti-CD4 (IgG2b, clone 74-12-4, BD
osciences), PE-conjugated anti-CD8a (IgG2a, clone 76-
11, BD Biosciences), Alexa488-conjugated anti-CD8b
G1, clone PPT23), Alexa647-conjugated anti-CD27
G1, clone b30c7, and biotinylated anti-TCR gd (IgG2b,
ne PPT16). All non-commercial monoclonal antibodies
aalmu¨ller, 1996) were produced at the Institute of
munology, Veterinary University, Vienna. These anti-
dies had been puriﬁed and covalently conjugated to
orochromes (Alexa Fluor Protein Labeling kits, Life
chnologies) or Biotin (Sulfo-NHS-LCBiotin, Thermo
ientiﬁc, Pierce, Vienna, Austria). Fixable Near-IR Dead
ll Stain Kit (Life Technologies) was used to discriminate
tween live and dead cells. FCM analyses were performed
 FACSCanto II (BD Biosciences). Data of at least 2.5  105
mphocytes per sample were recorded. Data were
alyzed with FACSDiva (Version 6.1.3, BD Biosciences)
d FlowJo (Version 10.0, Tree Star Inc, Ashland, OR, USA)
ftware.
 Results
As a surrogate of vaccine efﬁcacy, we ﬁrst used ELISpot
says to evaluate the frequency of IFN-g producing cells
ter in vitro re-stimulation with PRRSV. On SD14, all
imals in MLV group had a ELISpot count below the cut off
lue (Fig. 1). In contrast, the carbopol-MLV group included
ree animals (#19, #21 and #23) with a high number of
ots. On SD21, spots were readily detected in three animals
 the MLV group (#13, #14 and #18). Furthermore, the
me three animals that responded at SD14 in the carbopol-
LV group showed rather unchanged levels of IFN-g spots.
 expected, antigen-speciﬁc IFN-g production detected in
all SDs in the control groups (PBS and carbopol alone), as
well as in cells stimulated with mock virus or left
unstimulated fell under the cut off (not shown).
We next sought to study memory progression within
the CD4 T cell population on MLV and carbopol-MLV
groups. To this purpose, PBMC were labelled with a
ﬂuorescent dye, stimulated with PRRSV or mock virus
and analyzed by ﬂow cytometry four days later. Fig. 2
shows the gating strategy to deﬁne proliferating,
(CD4+Violetdim) and non proliferating (CD4+Violethigh)
cells (Fig. 2A), and to determine TCM and TEM cells
according to CD27 and CD8a expression (Fig. 2B). At
SD14, the overall percentage of PRRSV-speciﬁc prolifer-
ating CD4T helper cells (Fig. 2C), CD8b CTL, gd T cells, and
whole PBMC was similar between MLV and carbopol-
MLV groups (not shown). When analyzing surface marker
expression by CD4T cells in SD14 samples, we decided to
include animals of MLV group that did not produce IFN-g
early on but became responders at SD21 (#13, #14 and
#18), and compare them to #19, #21, and #23 of the MLV
carbopol group. This allowed us a direct comparison
between phenotype and function. The percentage of TCM
cells was heterogeneous in the three animals of the MLV
group (11.4%, 3.5% and 1.0%) compared to the three
responders of the carbopol-MLV group (9.3%, 4.9% and
12.3%) (Fig. 2C). In sharp contrast, a higher proportion of
TEM cells was detected in the three responder animals of
the carbopol-MLV group (25.7%, 9.6% and 22.7%) respect
to the MLV group (5.1%, 3.9% and 4.2%). Remarkably, the
proportion of total memory cells (TCM + TEM) was higher
in carbopol-MLV group (35%, 14.5% and 35%) than in MLV
group (16.5%, 7.4%, and 6.1%). Furthermore, the differ-
ences between MLV and carbopol-MLV groups detected
at SD14 were no longer so at SD21. Altogether, these data
suggest that carbopol promotes an early onset of cellular
immunity by facilitating T cell differentiation towards
effector phenotypes and by efﬁciently inducing naı¨ve to
memory transition.
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. 1. Frequency of IFN-g producing lymphocytes analyzed by ELISpot. The frequency of IFN-g producing cells of individual animals at SD14 (left panel) and
21 (right panel) is displayed within 3  105 PBMC at MOI = 1.0. Results are shown as mean of duplicates, including the standard deviation. Results are
own for the different stimulation groups: PBS, carbopol, MLV, and carbopol-MLV. The line indicates the cut off value. Responder animals have beenntiﬁed by #code.
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Due to its low reactivity, non virucidal nature and
fﬁcacy in one shot vaccination schedules carbopol, a
ghtly cross-linked polymer of acrylic acid, has become a
idely used adjuvant in the veterinary ﬁeld (Diamantstein
t al., 1971). In spite of wide applications, there is little
formation available relating to the type and magnitude
f adaptive immune response induced by carbopol
ompared to other well characterized adjuvants. Speciﬁ-
ally, the contribution of carbopol to enhance/modulate
ellular immunity of swine MLVs was not well studied.
lthough the precise immune pathways mediated by
arbopol remains to be understood, our data suggest that
ddition of carbopol to MLVs improves cellular responses
y inducing early IFN-g-producing cells and by preferen-
ally driving T cell differentiation to effector phenotypes.
he bias towards a Th1 phenotype is supported by human
reclinical studies where carbopol generated strong
ellular responses to soluble HIV-1 envelope glycoprotein
long with high IgG2a antibody titres (Krashias et al.,
010). Th1 responses are associated to increased CD8T cell
roliferation (Ekkens et al., 2007), production of opsoniz-
g antibodies (Lefeber et al., 2003) and maximizing
acrophage killing activity (Stout et al., 2005), thus
roviding an optimal milieu for anti-viral immunity.
portantly, the early generation of tissue-tropic effector
ells induced by carbopol may counteract the immune
scape mechanism evolved by PRRSV such as delayed
roduction of neutralizing antibodies, suppression of
terferon type-I IFNs, and up-regulation of IL-10 (Yoo
t al., 2010).
The immune response can vary greatly between
dividuals. Whereas most healthy vaccinated animals
evelop a quantiﬁable antibody response, a small percent-
ge of immunocompetent individuals fails to do so. The
latter are deﬁned as non-responders. Gene set enrichment-
based approach has been used to develop predictors of
human vaccine outcome, suggesting the genetic back-
ground as determinant in inducing immune responses
(Tan et al., 2014). Evidence for the impact of genetic
variation exists also for a number of livestock diseases
(Glass et al., 2012 and Cordes et al., 2012). In addition to
histocompatibility genes, microarray analysis showed
transcriptional differences in several immune-related
genes between high and low responders (Nino-Soto
et al., 2008). Genes identiﬁed as differentially expressed
include several critically involved in triggering immunity
such as cytokines and T cell receptor. Also, the frequency of
antigen speciﬁc cells varies among unexposed/non vacci-
nated individuals, therefore impacting responsiveness and
magnitude of immunity (Jenkins et al., 2012). With this in
mind, we would consider all the above as plausible
explanations as to why vaccination, not only of the
carbopol group but also in the non adjuvanted one, did
not result in the induction of the immune responses
measured (IFN-g production quantiﬁed by ELISpot and
CD4T cell phenotype) in all animals.
The precise mechanisms for the adjuvancy provided by
carbopol remain elusive. As far we know there are not
available data proving the half-life of carbopol once
injected in vivo, therefore making difﬁcult to ascribe its
beneﬁts to any time point after vaccination. Thus, although
the readouts used in the present study suggest that early
immune response can be modiﬁed in the presence of
carbopol (some hypotheses are discussed below), we
cannot rule out that carbopol could also impact late
responses.
The cross-linked network enables carbopol the entrap-
ment of drugs in the hydrogel domains, thus making
carbopol-based formulations optimal for release control of
small molecules (Singla et al., 2000). By extrapolation it has
ig. 2. Phenotype of in vitro activated, virus speciﬁc CD4T cells. SD14 PBMC were labelled with Violet Cell Trace and stimulated in vitro with PRRSV (example
own is swine #19). (A) Proliferating (1, Violetdim) and non proliferating (2, Violethigh) total lymphocytes were gated on CD4T helper cells (CD3+/CD4+). (B)
xpression of CD8a and CD27 in proliferating (left panel) and non proliferating (right panel) CD4T helper cells; CD8a+CD27, TEM; CD8a
+CD27+, TCM;
D8aCD27+, naı¨ve. (C) Frequencies of proliferating CD4T helper cells and CD4T cell subsets as deﬁned in A and B. Total memory = TCM + TEM. All percentages
f virus-stimulated cells were corrected by substraction of mock-stimulated cells.
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K.H. Mair et al. / Veterinary Microbiology 176 (2015) 352–357356en suggested, although not formally proven, that these
atures would endow carbopol with adjuvant properties
 exerting an antigen depot effect for single shot vaccines
ai et al., 2012). Should this be the case, it would provide
guments to support the differentiation to effector cells
served in our study (Reutner et al., 2013). Indeed, a
rsistent antigenic stimulation is known to induce a
eferential switch to effector over memory T cell
fferentiation (Lanzavecchia and Sallusto, 2005).
Dendritic cell (DC) activation triggered by the interac-
n between Toll-like receptors (TLR) expressed on DC
d TLR ligands carried by pathogens lead to immunity
evitz and Golenbock, 2012). Vaccinology is currently
ploiting this phenomenon to improve vaccine efﬁcacy,
hereby small molecules mimicking the action of TLR
onists are being added to vaccines as adjuvants
emento et al., 2009). To test the possibility of direct
tivation of DCs by carbopol, we generated dendritic cells
 vitro using recombinant porcine GM-CSF according to
utine protocols (Muss et al., 2013). After 6 days in
lture, immature DCs were exposed to increasing
lutions of carbopol or to LPS and phenotypical and
nctional responses were evaluated at different time
ints after stimulation. None of the conditions tried with
rbopol induced on DCs the expected signs of activation
hanges in the expression of surface markers such as
40, CD80 and CD86, and in TNF production; not shown),
ggesting the absence of alert receptors speciﬁc for the
lymeric structure of carbopol.
Other alternatives may explain the effect of carbopol on
mphocytes and the downstream outcome observed in
r in vivo study; for example, a local network environ-
ent could favour cell-to-cell interactions for optimal cell
tivation in peripheral tissues and subsequent cell
igration to draining lymph nodes. Also, the trapping of
luble immune mediators such as cytokines and chemo-
nes could result in better intercellular signalling and into
ore efﬁcient leukocyte recruitment to the site of vaccine
livery. Alternatively, carbopol action could rely on non-
mune cells, whose role in promoting immunity would
 revealed in subsequent time.
The identiﬁcation of immunological correlates alter-
tive to or complementing serological responses
mains a great challenge in modern vaccinology. When
tibodies cannot reﬂect vaccine performance, having
ditional readouts will be instrumental tools for vaccine
sign. The main goal of our exploratory study was
 identify such correlate candidates in the context of
clinical and economical relevant swine disease. As
ch, our data represents a ﬁrst step towards more
bitious validation settings where challenge will follow
ccination.
 Conclusion
In summary, here we have provided evidence for
rbopol to be a cellular enhancer and modulator of
mune responses. In settings where MLVs – not only
bunit-based or inactivated vaccines – are applied,
rmulation with this polymer may have beneﬁcial effects
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